Elevation Oncology — Corporate Update (May 2022)
21 slides from Elevation Oncology's corporate update, May 27, 2022
Slide 1: Initial CRESTONE Data Investor Conference Call
Initial CRESTONE Data Investor Conference Call MAY 26, 2022
Slide 2: Forward Looking Statements
Forward Looking Statements These slides contain forward - looking statements and information relating to Elevation Oncology, Inc. within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on fo
Slide 3: Today's Agenda
3 Today’s Agenda Introduction Shawn M. Leland, PharmD RPh FOUNDER AND CHIEF EXECUTIVE OFFICER Review of Data Valerie M. Jansen, MD PhD CHIEF MEDICAL OFFICER Clinical Perspective Daniel Carrizosa, MD ASSOCIATE PROFESSOR, MEDICAL ONCOLOGIST ATRIUM HEALTH, LEVINE CANCER INSTITUTE Closing Remarks Shawn
Slide 4: Introduction
4 Shawn M. Leland, PharmD RPh INTRODUCTION FOUNDER AND CHIEF EXECUTIVE OFFICER
Slide 5: Leading with Seribantumab and Strategy for Pipeline Expansion
5 Leading with Seribantumab and Strategy for Pipeline Expansion Well - characterized mAb targeting HER3 ● Potentially pursue earlier lines of therapy in NRG1 gene fusions ● Expand into additional genomically defined cancers MAXIMIZE LEAD PROGRAM SERIBANTUMAB ADVANCE NEW DISCOVERIES THROUGH CARIS COL
Slide 6: Review of Data
6 Valerie M. Jansen, MD PhD REVIEW OF DATA CHIEF MEDICAL OFFICER
Slide 7: NRG1 Gene Fusions in Solid Tumors
NRG1 Gene Fusions in Solid Tumors 7 ▪ NRG1 gene fusions are: o Rare genomic alterations resulting from the fusion of NRG1 with a partner gene¹ o NRG1 fusion proteins bind to and activate HER3¹ o Often mutually exclusive of other known oncogenic alterations² – ⁴ o Found in 0.2% of all solid tumors; •
Slide 8: Seribantumab (anti-HER3 mAb)
8 Seribantumab (anti - HER3 mAb ) POTENTIAL NOVEL TARGETED THERAPY FOR SOLID TUMORS DRIVEN BY AN NRG1 FUSION AND OTHER HER3 GENOMICALLY DEFINED CANCERS NRG1 Fusion Proteins SERIBANTUMAB Fully Human IgG2 anti - HER3 Monoclonal Antibody BLOCKS LIGAND - DEPENDENT ACTIVATION AND PHOSPHORYLATION OF HER3
Slide 9: CRESTONE: A Phase 2 Study of Seribantumab in Solid Tumors with NRG1 Fusions
CRESTONE: A Phase 2 Study of the Anti - HER3 mAb Seribantumab in Solid Tumors with NRG1 Fusions 9 Seribantumab 3g IV QW † SAFETY POPULATION Key Inclusion Criteria ✓ Patients with locally advanced or metastatic solid tumors harboring an NRG1 gene fusion (by local testing) ✓ Minimum 1 prior systemic t
Slide 10: Patient Demographics and Disease Characteristics
Patient Demographics and Disease Characteristics 10 DISEASE CHARACTERISTIC COHORT 1 † (N=15) SAFETY POPULATION ‡ (N=35) Primary Tumor Type; n (%) Biliary Tract/cholangiocarcinoma 0 2 (6) Breast 0 4 (11) NSCLC 14 (93) 20 (57) Pancreas 1 (7) 5 (14) Other § 0 4 (11) NRG1 Fusion Partners; n (%) ATP1B1 1
Slide 11: Seribantumab has been well-tolerated in patients with tumors harboring NRG1 fusions
11 Seribantumab has been well - tolerated in patients with tumors harboring NRG1 fusions †2 Grade 5 TEAEs (unrelated to seribantumab ) of lung infection (n=1 patient) and malignant neoplasm progression (n=1 patient); ‡No Grade 4 or 5 TRAEs reported; 2 Grade 3 TRAEs of diarrhea (n=1 patient) and vomi
Slide 12: Clinical Activity of Seribantumab in Tumors Harboring NRG1 Fusions
12 Clinical Activity of Seribantumab in Tumors Harboring NRG1 Fusions INVESTIGATOR - ASSESSED (INV) RESPONSE, % COHORT 1 PRIMARY EFFICACY POPULATION † ( N=12 ‡ ) COHORT 1 - NSCLC PRIMARY EFFICACY POPULATION † (N=11 ‡ ) Objective response rate; n (%) 4 (33) 4 (36) Complete response; n (%) 2 (17) 2 (1
Slide 13: Efficacy of Seribantumab in Tumors Harboring NRG1 Fusions
13 Efficacy of Seribantumab in Tumors Harboring NRG1 Fusions Lung/NSCLC Pancreas Primary tumor type: PD SD SD SD SD SD SD † PR PR SD ‡ CR CR 60 40 20 0 – 20 – 40 – 60 – 80 – 100 PERCENTAGE CHANGE FROM BASELINE 92% of patients had tumor reduction from baseline per RECIST v1.1 †Unconfirmed PR, unable
Slide 14: Duration of Seribantumab Therapy in Tumors Harboring NRG1 Fusions
14 Duration of Seribantumab Therapy in Tumors Harboring NRG1 Fusions Visit cut - off: 18 April 2022 0 2 4 6 8 10 12 14 16 18 TIME FROM START OF TREATMENT (MONTHS) Treatment ongoing Confirmed CR Confirmed PR Unconfirmed PR Lung/NSCLC Pancreas Primary tumor type: OVERALL RESPONSE PR CR PR CR ● 75% of
Slide 15: Case Study of Patient with CD74-NRG1 NSCLC Shows Durable Response
15 Case Study of Patient with CD74 - NRG1 NSCLC Shows Durable Response Images courtesy of Tejas Patil, MD; University of Colorado Visit cut - off: 18 April 2022 BASELINE WEEK 24 -100 -80 -60 -40 -20 0 20 40 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 TARGET LESION CHANGE (%) TIME FROM START OF TREATMENT (
Slide 16: Case Study of Patient with ITGB1-NRG1 NSCLC Shows Deep and Durable Response
16 Case Study of Patient with ITGB1 - NRG1 NSCLC Shows Deep and Durable Response Images courtesy of Daniel R. Carrizosa, MD; Levine Cancer Institute Visit cut - off: 18 April 2022 BASELINE WEEK 24 -100 -80 -60 -40 -20 0 20 40 0 1 2 3 4 5 6 7 8 9 10 11 12 TARGET LESION CHANGE (%) TIME FROM START OF T
Slide 17: Initial CRESTONE Data: Seribantumab is a Potential Best-in-Class Therapy
17 Initial CRESTONE Data: Seribantumab is a Potential Best - in - Class Therapy S howing D eep and Durable Benefit for Patients 33% INV - ORR 2 CRs, 2 PRs 36% INV - ORR in NSCLC 92% Disease Control Rate DoR range 1 ..4 - 11.5 months Well - tolerated safety profile Unmet medical need with no approved
Slide 18: Clinical Perspective
18 CLINICAL PERSPECTIVE Daniel Carrizosa, MD ASSOCIATE PROFESSOR, MEDICAL ONCOLOGIST ATRIUM HEALTH, LEVINE CANCER INSTITUTE
Slide 19: Introduction
19 Shawn M. Leland, PharmD RPh INTRODUCTION FOUNDER AND CHIEF EXECUTIVE OFFICER
Slide 20: Upcoming Milestones
Mid - 2022 CRESTONE | Complete enrollment of first 20 patients in Cohort 1 First Half 2023 CRESTONE | Report additional interim data from Cohort 1 2024 CRESTONE | Report topline data from Cohort 1 Ongoing target evaluation and continued execution of our strategy for pipeline expansion Collaboration
Slide 21: Q&A
Q&A Shawn M. Leland, PharmD RPh Founder and Chief Executive Officer Valerie M. Jansen, MD PhD Chief Medical Officer Joseph Ferra Chief Financial Officer David Dornan, PhD Chief Scientific Officer Daniel Carrizosa, MD Associate Professor, Medical Oncologist Atrium Health, Levine Cancer Institute